Literature DB >> 22676366

Decreased maternal plasma apelin concentrations in preeclampsia.

Katherine D Bortoff1, Chunfang Qiu, Scott Runyon, Michelle A Williams, Rangan Maitra.   

Abstract

BACKGROUND: Preeclampsia is a hypertensive disorder that complicates 3-7% of pregnancies. The development of preeclampsia has not been completely elucidated and current therapies are not broadly efficacious. The apelinergic system appears to be involved in hypertensive disorders and experimental studies indicate a role of this system in preeclampsia. Thus, an epidemiological evaluation of apelin protein concentration in plasma was conducted in case-control study of pregnant women.
METHODS: Data and maternal plasma samples were collected from pregnant women with confirmed preeclampsia (n = 76) or normotensive controls (n = 79). Concentrations of apelin peptides were blindly measured using enzyme-linked immunosorbent assay. Data were subjected to statistical analyses.
RESULTS: Plasma apelin concentrations, measured at delivery, were lower in preeclampsia cases compared with controls (mean ± standard deviation: 0.66 ± 0.29 vs. 0.78 ± 0.31 ng/mL, p = 0.02). After controlling for confounding by maternal age, smoking status, and pre-pregnancy body mass index, odds of preeclampsia were 48% lower for women with high versus low plasma apelin (≥0.73 vs. <0.73 ng/mL) concentrations.
CONCLUSION: Reduced circulating apelin peptides may be associated with preeclampsia. The apelinergic system should be further investigated to elucidate its role in preclampsia and other hypertensive maternal disorders.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22676366     DOI: 10.3109/10641955.2012.690054

Source DB:  PubMed          Journal:  Hypertens Pregnancy        ISSN: 1064-1955            Impact factor:   2.108


  8 in total

Review 1.  From apelin to exercise: emerging therapies for management of hypertension in pregnancy.

Authors:  Jeffrey S Gilbert
Journal:  Hypertens Res       Date:  2017-04-06       Impact factor: 3.872

Review 2.  G-Protein-coupled receptors as potential drug candidates in preeclampsia: targeting the relaxin/insulin-like family peptide receptor 1 for treatment and prevention.

Authors:  Kirk P Conrad
Journal:  Hum Reprod Update       Date:  2016-07-06       Impact factor: 15.610

3.  Apelin as a novel drug for treating preeclampsia.

Authors:  Chengshu Wang; Xiaoli Liu; Desheng Kong; Xijing Qin; Yanqing Li; Xu Teng; Xianghua Huang
Journal:  Exp Ther Med       Date:  2017-10-13       Impact factor: 2.447

Review 4.  Involvement of Novel Adipokines, Chemerin, Visfatin, Resistin and Apelin in Reproductive Functions in Normal and Pathological Conditions in Humans and Animal Models.

Authors:  Anthony Estienne; Alice Bongrani; Maxime Reverchon; Christelle Ramé; Pierre-Henri Ducluzeau; Pascal Froment; Joëlle Dupont
Journal:  Int J Mol Sci       Date:  2019-09-09       Impact factor: 5.923

Review 5.  The Role of the Adipokines in the Most Common Gestational Complications.

Authors:  Paweł Gutaj; Rafał Sibiak; Maurycy Jankowski; Karina Awdi; Rut Bryl; Paul Mozdziak; Bartosz Kempisty; Ewa Wender-Ozegowska
Journal:  Int J Mol Sci       Date:  2020-12-10       Impact factor: 5.923

Review 6.  Apelin, APJ, and ELABELA: Role in Placental Function, Pregnancy, and Foetal Development-An Overview.

Authors:  Monika Dawid; Ewa Mlyczyńska; Małgorzata Jurek; Natalia Respekta; Karolina Pich; Patrycja Kurowska; Wiktoria Gieras; Tomasz Milewicz; Małgorzata Kotula-Balak; Agnieszka Rak
Journal:  Cells       Date:  2021-12-29       Impact factor: 6.600

7.  Clinicopathological study of annexin A5 & apelin in pre-eclamptic placentae with emphasis on foetal outcome.

Authors:  Senjuti Dasgupta; Priyanka Maity; Uma Banerjee; Partha Mukhopadhyay; Saswata Saha; Biplab Das
Journal:  Indian J Med Res       Date:  2021-06       Impact factor: 5.274

Review 8.  Possible roles of exercise and apelin against pregnancy complications.

Authors:  Hamed Alizadeh Pahlavani
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-25       Impact factor: 6.055

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.